SA
NVCR icon

SpiderRock Advisors’s NovoCure NVCR Stock Holding History

SpiderRock Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.26M Hold
80,693
– – 0.02% 423
2024
Q2 		$1.38M Sell
80,693
-7,308
-8% -$129K 0.03% 353
2024
Q1 		$1.22M Buy
+88,001
New +$1.29M 0.03% 365

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $652M AUM 36.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SpiderRock Advisors's NVCR Position: Q3 2024 in Review

SpiderRock Advisors held its NovoCure (NVCR) position steady in Q3 2024 at 80,693 shares worth $1.26M. The position accounts for 0.02% of the portfolio, ranked #423.

SpiderRock Advisors first reported a position in NVCR in Q1 2024 and has held it in 3 quarters since. The position peaked at $1.38M in Q2 2024. 225 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

  • SpiderRock Advisors held 80,693 shares of NovoCure worth $1.26M as of Q3 2024.
  • SpiderRock Advisors left its NovoCure share count unchanged in Q3 2024.
  • NovoCure made up 0.02% of SpiderRock Advisors's portfolio in Q3 2024, its #423 holding.
  • SpiderRock Advisors first reported a position in NovoCure in Q1 2024 and has held it in 3 quarters since.
  • SpiderRock Advisors's NovoCure position peaked at $1.38M in Q2 2024.
  • 225 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.